Article citationsMore>>

Gao, Y., Kong, F., Song, X., Shang, J., Yao, L., Xia, J., Peng, Y., Liu, W., Gong, H., Mu, M., Cui, H., Han, T., Chen, W., Wu, X., Yang, Y., Yan, X., Jin, Z., Wang, P., Zhu, Q., Chen, L., Zhao, C., Zhang, D., Jin, W., Wang, D., Wen, X., Liu, C., Jia, J., Mao, Q., Ding, Y., Jin, X., Zhang, Z., Mao, Q., Li, G. and Niu, J. (2022) Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 74, 1925-1932.
https://doi.org/10.1093/cid/ciab763

has been cited by the following article:

• TITLE: Mechanisms of Targeted Drug Delivery for Liver Cancer: Active, Passive, and Subcellular Strategies

  AUTHORS: Yang Tian, Yusheng Shi

  KEYWORDS: Targeted Drug Delivery, Hepatocellular Carcinoma (HCC), Active Targeting, Subcellular Targeting, Nanomedicine

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.2, February 21, 2025

  ABSTRACT: This article provides a comprehensive review of various approaches to targeted drug delivery for liver cancer, an area of significant need due to the limited effectiveness of current treatments. The article begins by highlighting the role of the liver in metabolism and discusses the high mortality associated with hepatocellular carcinoma (HCC). The shortcomings of traditional chemotherapy, such as multidrug resistance and off-target effects, necessitate the exploration of novel therapeutic strategies, with a focus on targeted approaches. The review details both passive and active targeting strategies. Passive targeting leverages the enhanced permeability and retention (EPR) effect and unique features of the tumor microenvironment, while active targeting employs specific ligands, such as peptides, antibodies, and proteins, to bind to overexpressed receptors on liver and tumor cells. The article further details many examples of active targeting using the asialoglycoprotein receptor (ASGPR), glycyrrhetinic acid (GA), transferrin receptor (TfR), and folate receptor (FR) on hepatocytes and tumor cells, demonstrating that there has been significant research effort put into this field. The importance of non-parenchymal cells in the liver is also discussed, and the article examines methods of targeting Kupffer cells, sinusoidal endothelial cells, and hepatic stellate cells for therapeutic benefit. The review goes on to cover the emerging field of subcellular targeting, including specific strategies to target the nucleus, mitochondria, and the endoplasmic reticulum/Golgi apparatus, noting that although there has been some progress, further research is needed in this area. The text finishes with a summary which acknowledges that while targeted therapies, including enzyme-activated prodrugs, such as Pradefovir, and other novel methods for drug delivery have shown significant promise, challenges remain in translating these therapies into clinical use due to limitations in understanding the sequential transport and the mechanisms of action. Ultimately, the article emphasizes the need for in-depth research to fully realize the potential of precision cancer therapies for liver cancer.